- Home
- ENSC vs XXII Comparison
ENSC vs XXII Comparison
Compare ENSC & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- XXII
- Stock Information
- Founded
- ENSC 2003
- XXII 1998
- Country
- ENSC United States
- XXII United States
- Employees
- ENSC N/A
- XXII N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- XXII Medicinal Chemicals and Botanical Products
- Sector
- ENSC Health Care
- XXII Health Care
- Exchange
- ENSC Nasdaq
- XXII Nasdaq
- Market Cap
- ENSC 6.4M
- XXII 6.2M
- IPO Year
- ENSC N/A
- XXII N/A
- Fundamental
- Price
- ENSC $2.18
- XXII $1.51
- Analyst Decision
- ENSC
- XXII
- Analyst Count
- ENSC 0
- XXII 0
- Target Price
- ENSC N/A
- XXII N/A
- AVG Volume (30 Days)
- ENSC 157.0K
- XXII 1.3M
- Earning Date
- ENSC 11-07-2025
- XXII 11-04-2025
- Dividend Yield
- ENSC N/A
- XXII N/A
- EPS Growth
- ENSC N/A
- XXII N/A
- EPS
- ENSC N/A
- XXII N/A
- Revenue
- ENSC $7,413,722.00
- XXII $21,362,000.00
- Revenue This Year
- ENSC N/A
- XXII N/A
- Revenue Next Year
- ENSC N/A
- XXII $126.57
- P/E Ratio
- ENSC N/A
- XXII N/A
- Revenue Growth
- ENSC 415.58
- XXII N/A
- 52 Week Low
- ENSC $1.62
- XXII $1.43
- 52 Week High
- ENSC $14.67
- XXII $394.02
- Technical
- Relative Strength Index (RSI)
- ENSC 46.48
- XXII 45.23
- Support Level
- ENSC $2.04
- XXII $1.48
- Resistance Level
- ENSC $2.23
- XXII $1.80
- Average True Range (ATR)
- ENSC 0.19
- XXII 0.09
- MACD
- ENSC -0.03
- XXII 0.02
- Stochastic Oscillator
- ENSC 20.83
- XXII 21.62
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.